Table 1. The course of clinical and laboratory features in patients with SSc.

	Baseline	1 year follow-up	2 year follow-up	3 year follow-up	4 year follow-up
MRSS	16 (2–39)	10 (0–38)	12 (0–35)	9 (1–25)	8 (0–29)
And meto	96 (53–143)	91 (62–143)	95 (61–143)	91 (56–137)	90 (58–136)
HAQ-DI	0.125 (0–1.5)	0.125 (0–1.75)	0.25 (0–2.5)	0.125 (0–1.875)	0.25 (0–1.75)
ILD	30 (77%)	30 (77%)	31 (79%)	32 (82%)	32 (82%)
Renal crisis	0 (0%)	2 (5.1%)	0 (0%)	1 (2.6%)	1 (2.6%)
Corticosteroid therapy	26 (67%)	32 (82%)	33 (85%)	34 (87%)	32 (82%)
Cyclophosphamide therapy	4 (10%)	8 (21%)	4 (10%)	6 (15%)	8 (21%)
Cyclosporin A therapy	0 (0%)	1 (3%)	2 (5%)	4 (10%)	4 (10%)
Azathioprine therapy	0 (0%)	0 (0%)	1 (3%)	1 (3%)	1 (3%)
Methotrexate therapy	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (3%)

Values are represented as median (range) or as number of positive cases with percentage within parentheses.